Research programme: hearing loss therapeutics - Otonomy

Drug Profile

Research programme: hearing loss therapeutics - Otonomy

Alternative Names: OTO 413; OTO 5XX; OTO 6XX; Sensorineural therapeutics - Otonomy

Latest Information Update: 23 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otonomy; University of California System
  • Developer Otonomy
  • Class Proteins; Small molecules
  • Mechanism of Action Brain derived neurotrophic factor agonists; Neurotransmitter stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hearing loss

Most Recent Events

  • 08 Mar 2018 Otonomy has patent protection for OTO 413, under a license with the Regents of the University of California as well as solely, in USA and other countries worldwide
  • 06 Feb 2018 Otonomy plans a phase I/II trial in Hearing loss in first half of 2019
  • 06 Feb 2018 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top